These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 8891133)

  • 21. [Effect of linezolid in combination with isoniazid and rifampicin against multidrug resistant Mycobacterium tuberculosis clinical isolates].
    Coban AY; Bilgin K; Uzun M; Durupinar B
    Mikrobiyol Bul; 2009 Apr; 43(2):293-7. PubMed ID: 19621615
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative study of the bactericidal activity of ampicillin/sulbactam and erythromycin against intracellular Legionella pneumophila.
    Ramirez JA; Summersgill JT; Miller RD; Meyers TL; Raff MJ
    J Antimicrob Chemother; 1993 Jul; 32(1):93-9. PubMed ID: 8226420
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of mycobacteria growth indicator tubes for susceptibility testing of Mycobacterium tuberculosis to isoniazid and rifampin.
    Reisner BS; Gatson AM; Woods GL
    Diagn Microbiol Infect Dis; 1995 Aug; 22(4):325-9. PubMed ID: 8582137
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effect of levofloxacine on cell elements of the lung tissue and on the growth of drug resistant Mycobacteria tuberculosis].
    Sokolova GB; Semenova OV; Bogadel'nikova IV; Kunichan AD
    Antibiot Khimioter; 2002; 47(6):12-7. PubMed ID: 12422642
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Determination of in vitro synergy when three antimicrobial agents are combined against Mycobacterium tuberculosis.
    Bhusal Y; Shiohira CM; Yamane N
    Int J Antimicrob Agents; 2005 Oct; 26(4):292-7. PubMed ID: 16150578
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the bactericidal activity of various fluoroquinolones against Mycobacterium tuberculosis in an in vitro experimental model.
    Cremades R; Rodríguez JC; García-Pachón E; Galiana A; Ruiz-García M; López P; Royo G
    J Antimicrob Chemother; 2011 Oct; 66(10):2281-3. PubMed ID: 21733966
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antituberculosis activity of clarithromycin.
    Luna-Herrera J; Reddy VM; Daneluzzi D; Gangadharam PR
    Antimicrob Agents Chemother; 1995 Dec; 39(12):2692-5. PubMed ID: 8593004
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro activity of C-8-methoxy fluoroquinolones against mycobacteria when combined with anti-tuberculosis agents.
    Lu T; Drlica K
    J Antimicrob Chemother; 2003 Dec; 52(6):1025-8. PubMed ID: 14613961
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessing the Combined Antibacterial Effect of Isoniazid and Rifampin on Four Mycobacterium tuberculosis Strains Using
    Genestet C; Ader F; Pichat C; Lina G; Dumitrescu O; Goutelle S
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29061753
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rapid genotypic detection of rifampin- and isoniazid-resistant Mycobacterium tuberculosis directly in clinical specimens.
    Bang D; Bengård Andersen A; Thomsen VØ
    J Clin Microbiol; 2006 Jul; 44(7):2605-8. PubMed ID: 16825393
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Bactericidal therapy in patients with tuberculosis].
    Krasnov VA; Ursov IG
    Probl Tuberk Bolezn Legk; 2004; (3):21-6. PubMed ID: 15338895
    [No Abstract]   [Full Text] [Related]  

  • 32. The combination of sulfamethoxazole, trimethoprim, and isoniazid or rifampin is bactericidal and prevents the emergence of drug resistance in Mycobacterium tuberculosis.
    Vilchèze C; Jacobs WR
    Antimicrob Agents Chemother; 2012 Oct; 56(10):5142-8. PubMed ID: 22825115
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis.
    Somoskovi A; Parsons LM; Salfinger M
    Respir Res; 2001; 2(3):164-8. PubMed ID: 11686881
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth.
    Gumbo T; Louie A; Liu W; Ambrose PG; Bhavnani SM; Brown D; Drusano GL
    J Infect Dis; 2007 Jan; 195(2):194-201. PubMed ID: 17191164
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emergence during unsuccessful chemotherapy of multiple drug resistance in a strain of Mycobacterium tuberculosis.
    Rastogi N; Ross BC; Dwyer B; Goh KS; Clavel-Sérès S; Jeantils V; Cruaud P
    Eur J Clin Microbiol Infect Dis; 1992 Oct; 11(10):901-7. PubMed ID: 1362540
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bacteriostatic and bactericidal activity of antituberculosis drugs against Mycobacterium tuberculosis, Mycobacterium avium-Mycobacterium intracellulare complex and Mycobacterium kansasii in different growth phases.
    Yamori S; Ichiyama S; Shimokata K; Tsukamura M
    Microbiol Immunol; 1992; 36(4):361-8. PubMed ID: 1406364
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination of anti-tuberculosis drugs with vitamin C or NAC against different Staphylococcus aureus and Mycobacterium tuberculosis strains.
    Khameneh B; Fazly Bazzaz BS; Amani A; Rostami J; Vahdati-Mashhadian N
    Microb Pathog; 2016 Apr; 93():83-7. PubMed ID: 26602814
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lack of correlation between embB mutation and ethambutol MIC in Mycobacterium tuberculosis clinical isolates from China.
    Shi R; Zhang J; Otomo K; Zhang G; Sugawara I
    Antimicrob Agents Chemother; 2007 Dec; 51(12):4515-7. PubMed ID: 17846128
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of ofloxacin against Mycobacterium tuberculosis and Mycobacterium avium, and rifampin against M. tuberculosis in cultured human macrophages.
    Crowle AJ; Elkins N; May MH
    Am Rev Respir Dis; 1988 May; 137(5):1141-6. PubMed ID: 3143278
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy.
    de Knegt GJ; ten Kate MT; van Soolingen D; Aarnoutse R; Boeree MJ; Bakker-Woudenberg IA; de Steenwinkel JE
    Tuberculosis (Edinb); 2014 Dec; 94(6):701-7. PubMed ID: 25621361
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.